The relationship between elevated serum xenin and insulin resistance in women with polycystic ovary syndrome: a case-control study

Güçlü, Yusuf Adnan; Şahin, Ethem; Akşit, Murat

doi:10.1080/09513590.2019.1604663

Cited by 4 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, levels of DHEA (dehydroepiandrosterone), insulin, HbA1c (glycosylated haemoglobin) and LDL-c (low-density lipoprotein-cholesterol) could be used for the early diagnosis of PCOS [69]. Xenin, an ancient regulatory peptide [70] known as a regulator of insulin and glucagon secretion (thereby an important therapeutic target in DM and obesity [71]), was also shown to be a factor of PCOS pathogenesis [72].…”

Section: Novel Markers For Pcos Diagnosismentioning

confidence: 99%

Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome

Dabravolski

Nikiforov

Eid

et al. 2021

IJMS

View full text Add to dashboard Cite

Polycystic ovarian syndrome (PCOS) is the most common endocrine–metabolic disorder affecting a vast population worldwide; it is linked with anovulation, mitochondrial dysfunctions and hormonal disbalance. Mutations in mtDNA have been identified in PCOS patients and likely play an important role in PCOS aetiology and pathogenesis; however, their causative role in PCOS development requires further investigation. As a low-grade chronic inflammation disease, PCOS patients have permanently elevated levels of inflammatory markers (TNF-α, CRP, IL-6, IL-8, IL-18). In this review, we summarise recent data regarding the role of mtDNA mutations and mitochondrial malfunctions in PCOS pathogenesis. Furthermore, we discuss recent papers dedicated to the identification of novel biomarkers for early PCOS diagnosis. Finally, traditional and new mitochondria-targeted treatments are discussed. This review intends to emphasise the key role of oxidative stress and chronic inflammation in PCOS pathogenesis; however, the exact molecular mechanism is mostly unknown and requires further investigation.

show abstract

Section: Novel Markers For Pcos Diagnosismentioning

confidence: 99%

Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome

Dabravolski

Nikiforov

Eid

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…In terms of its association to PCOS, so far, only one study assessing the concentration of this peptide has been conducted [ 33 ]. It demonstrated that xenin-25 levels were significantly increased in a small group of 31 women with PCOS compared to the control group of 30 healthy, regularly menstruating women.…”

Section: Xeninmentioning

confidence: 99%

“…The optimal cutoff value of xenin-25 for predicting PCOS was 32.60 pg/mL, giving a sensitivity of 61.3% and a specificity of 86.7%. The groups did not differ from each other regarding markers of insulin sensitivity [ 33 ].…”

Section: Xeninmentioning

confidence: 99%

Review of Novel Potential Insulin Resistance Biomarkers in PCOS Patients—The Debate Is Still Open

Kruszewska

Laudy-Wiaderny²,

Kunicki

2022

IJERPH

View full text Add to dashboard Cite

Research on proteins and peptides that play roles in metabolic regulation, which may be considered potential insulin resistance markers in some medical conditions, such as diabetes mellitus, obesity and polycystic ovarian syndrome (PCOS), has recently gained in interest. PCOS is a common endocrine disorder associated with hyperandrogenemia and failure of ovulation, which is often accompanied by metabolic abnormalities, including obesity, dyslipidemia, hyperinsulinemia, and insulin resistance. In this review, we focus on less commonly known peptides/proteins and investigate their role as potential biomarkers for insulin resistance in females affected by PCOS. We summarize studies comparing the serum fasting concentration of particular agents in PCOS individuals and healthy controls. Based on our analysis, we propose that, in the majority of studies, the levels of nesfastin-1, myonectin, omentin, neudesin were decreased in PCOS patients, while the levels of the other considered agents (e.g., preptin, gremlin-1, neuregulin-4, xenopsin-related peptide, xenin-25, and galectin-3) were increased. However, there also exist studies presenting contrary results; in particular, most data existing for lipocalin-2 are inconsistent. Therefore, further research is required to confirm those hypotheses, as well as to elucidate the involvement of these factors in PCOS-related metabolic complications.

show abstract

“… 45 In this regard, serum xenin concentrations are significantly elevated in women with PCOS compared to women with no menstrual cycle abnormalities. 46 However, as with diabetes, 6 the precise impact of xenin in PCOS and its pathophysiology remains to be fully elucidated. When viewed together, the above diverse biological actions of xenin emphasise potential for targeting related pathways for the amelioration of insulin resistance and related disease such as diabetes and PCOS.…”

Section: Function Potential Mechanism Of Action and Therapeutic Application Of Xeninmentioning

confidence: 99%

Xenin and Related Peptides: Potential Therapeutic Role in Diabetes and Related Metabolic Disorders

Craig

Irwin

Gault

2021

Clin Med Insights Endocrinol Diabetes

View full text Add to dashboard Cite

Xenin bioactivity and its role in normal physiology has been investigated by several research groups since its discovery in 1992. The 25 amino acid peptide hormone is secreted from the same enteroendocrine K-cells as the incretin hormone glucose-dependent insulinotropic polypeptide (GIP), with early studies highlighting the biological significance of xenin in the gastrointestinal tract, along with effects on satiety. Recently there has been more focus directed towards the role of xenin in insulin secretion and potential for diabetes therapies, especially through its ability to potentiate the insulinotropic actions of GIP as well as utilisation in dual/triple acting gut hormone therapeutic approaches. Currently, there is a lack of clinically approved therapies aimed at restoring GIP bioactivity in type 2 diabetes mellitus, thus xenin could hold real promise as a diabetes therapy. The biological actions of xenin, including its ability to augment insulin secretion, induce satiety effects, as well as restoring GIP sensitivity, earmark this peptide as an attractive antidiabetic candidate. This minireview will focus on the multiple biological actions of xenin, together with its proposed mechanism of action and potential benefits for the treatment of metabolic diseases such as diabetes.

show abstract

The relationship between elevated serum xenin and insulin resistance in women with polycystic ovary syndrome: a case-control study

Cited by 4 publications

References 27 publications

Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome

Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome

Review of Novel Potential Insulin Resistance Biomarkers in PCOS Patients—The Debate Is Still Open

Xenin and Related Peptides: Potential Therapeutic Role in Diabetes and Related Metabolic Disorders

Contact Info

Product

Resources

About